With advancements in drug design, there is resurging interest in drugs that form covalent bonds with their targets, often referred to as targeted covalent inhibitors (TCIs).  In this webinar, experts discuss innovative approaches to screen for covalent binders, strategies for the synthesis of covalent warheads, and assays to optimize the ADME/DMPK properties of these molecules. …Read More >

Casein kinase 2-interacting protein-1 (CKIP-1) performs a critical negative role in the regulation of bone formation. Accumulated evidence strongly supports CKIP-1 as an attractive therapeutic target in osteoporosis.  As a scaffold protein lacking enzymatic activity, CKIP-1 seems to be an undruggable target, and the development of selective small molecule inhibitors targeting CKIP-1 has proven to …Read More >

Introduction Membrane proteins are essential for various cellular processes, including energy conversion, signal transduction, and disease progression. Efficient and accurate identification and screening of these proteins are vital for the development of small-molecule therapeutics targeting membrane proteins. In recent years, Affinity Selection Mass Spectrometry (ASMS) has become a powerful tool for studying membrane protein-small molecule …Read More >

Rheumatoid arthritis (RA) is a prevalent, chronic, autoimmune disease. The onset and progression of RA are closely associated with an aberrant immune response, in which immune cells accumulate excessively in target joints.  Most current, anti-rheumatic drugs only alleviate disease progression or ameliorate inflammation. Development of new RA therapies with increased efficacy represents an unmet medical …Read More >

Introduction: New modalities, such as molecular glues, require robust screening strategies to identify and develop the most promising candidates efficiently. In this article, we spotlight Affinity Selection Mass Spectrometry (ASMS), a versatile and cost-effective high-throughput screening technique used in drug discovery. ASMS: A Powerful High-throughput Screening Technology Since the mid-1990s, ASMS has emerged as a …Read More >

OncoWuXi Express will continue to keep you informed about updates to our online tumor model database (OncoWuXi Database), as well as our recent progress in cancer and autoimmune research. In this issue, we would like to share our experience with mRNA drug development and their anti-tumor efficacy. OncoWuXi Introduction to Nucleic Acid Drugs RNA-based therapies …Read More >

Research on cancer immunotherapy has firmly established immune cells as key players in effective cancer treatment. Peptide vaccines directly targeting immune cells have demonstrated immense potential due to their specificity and applicability, but developing peptide vaccines to generate tumor-reactive T cells remains challenging. WuXi AppTec contributed to a review article discussing various elements of effective …Read More >

In recent years, bispecific antibodies (BsAbs) have emerged as a novel strategy in tumor immunotherapy. BsAbs combine two distinct antigen targets within a single antibody molecule, potentially enhancing clinical efficacy and safety. As a result of this dual targeting approach, the clinical therapeutic effects of BsAbs are considered superior to those of monoclonal antibodies. WuXi …Read More >

Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia in Western populations. Targeted therapies, including the use of BTK inhibitors, have significantly improved the care of patients with CLL. However, over time, many patients develop resistance to these drugs. Acquired resistance to the BTK inhibitor ibrutinib is mediated by the C481S mutation, …Read More >